Indications for 5-aminosalicylate in inflammatory bowel disease： IS the body of evidence complete
Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and concomitant drug pharmacokinetics, or in chemoprevention against-inflammatory bowel diseas...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2006-10, Vol.12 (38), p.6115-6123 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6123 |
|---|---|
| container_issue | 38 |
| container_start_page | 6115 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 12 |
| creator | van Bodegraven, A A Mulder, Chris J J |
| description | Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and concomitant drug pharmacokinetics, or in chemoprevention against-inflammatory bowel disease （IBD）-related colonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance. Therefore, due to its superior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, paediatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use. |
| doi_str_mv | 10.3748/wjg.v12.i38.6115 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4088103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>23139956</cqvip_id><wanfj_id>wjg200638005</wanfj_id><sourcerecordid>wjg200638005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-7f1f85907fccf17dbcf68638d85e85051f2fd5cdadfeb6361b662b5255338a373</originalsourceid><addsrcrecordid>eNpVkd1qGzEQhUVpaJyf-1wVUXq7rn6slfamUEKTGgK9SHIttNLIlrMruauNjV8lz9J36itExqZtQDCgOXPmMB9CV5RMuZypL9vVYrqhbBq4mtaUindowhhtKqZm5D2aUEJk1XAmT9FZzitCGOeCfUCnVBJec0UnyM6jC9aMIcWMfRqwqEwfYsqmC3bXmRFwiOX5zvS9GdOww23aQoddyGAy_Pn9guf3eFxC-Xc7nDyGTXAQLWCb-nUHI1ygE2-6DJfHeo4eb74_XP-o7n7ezq-_3VV2JsVYSU-9Eg2R3lpPpWutr1VJ6ZQAJYignnknrDPOQ1vzmrZ1zVrBhOBcGS75Ofp68F0_tz04C3EcTKfXQ-jNsNPJBP22E8NSL9JGz4hSlPBi8PlgsDXRm7jQq_Q8xBJZl0MzQkoYQkSRkYPMDinnAfzfFZToPZe9XBcuunDRey5l5OP_0f4NHEEUwaej5zLFxa9QlrfGPvnQgWac8qYRNX8FKxWY9A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Indications for 5-aminosalicylate in inflammatory bowel disease： IS the body of evidence complete</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>van Bodegraven, A A ; Mulder, Chris J J</creator><creatorcontrib>van Bodegraven, A A ; Mulder, Chris J J</creatorcontrib><description>Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and concomitant drug pharmacokinetics, or in chemoprevention against-inflammatory bowel disease （IBD）-related colonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance. Therefore, due to its superior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, paediatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v12.i38.6115</identifier><identifier>PMID: 17036381</identifier><language>eng</language><publisher>United States: Section of Inflammatory Bowel Diseases,VU University medical centre, Amsterdam, The Netherlands%Department of Gastroenterology, VU University medical centre, Amsterdam, The Netherlands</publisher><subject>Adenocarcinoma - prevention & control ; Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Colonic Neoplasms - prevention & control ; Humans ; Inflammatory Bowel Diseases - drug therapy ; Mesalamine - pharmacokinetics ; Mesalamine - therapeutic use ; Review ; Sulfasalazine - therapeutic use ; Treatment Failure ; Treatment Refusal ; 病理机制 ; 结肠疾病 ; 肠道炎症</subject><ispartof>World journal of gastroenterology : WJG, 2006-10, Vol.12 (38), p.6115-6123</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-7f1f85907fccf17dbcf68638d85e85051f2fd5cdadfeb6361b662b5255338a373</citedby><cites>FETCH-LOGICAL-c475t-7f1f85907fccf17dbcf68638d85e85051f2fd5cdadfeb6361b662b5255338a373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088103/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088103/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17036381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Bodegraven, A A</creatorcontrib><creatorcontrib>Mulder, Chris J J</creatorcontrib><title>Indications for 5-aminosalicylate in inflammatory bowel disease： IS the body of evidence complete</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and concomitant drug pharmacokinetics, or in chemoprevention against-inflammatory bowel disease （IBD）-related colonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance. Therefore, due to its superior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, paediatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use.</description><subject>Adenocarcinoma - prevention & control</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Colonic Neoplasms - prevention & control</subject><subject>Humans</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Mesalamine - pharmacokinetics</subject><subject>Mesalamine - therapeutic use</subject><subject>Review</subject><subject>Sulfasalazine - therapeutic use</subject><subject>Treatment Failure</subject><subject>Treatment Refusal</subject><subject>病理机制</subject><subject>结肠疾病</subject><subject>肠道炎症</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkd1qGzEQhUVpaJyf-1wVUXq7rn6slfamUEKTGgK9SHIttNLIlrMruauNjV8lz9J36itExqZtQDCgOXPmMB9CV5RMuZypL9vVYrqhbBq4mtaUindowhhtKqZm5D2aUEJk1XAmT9FZzitCGOeCfUCnVBJec0UnyM6jC9aMIcWMfRqwqEwfYsqmC3bXmRFwiOX5zvS9GdOww23aQoddyGAy_Pn9guf3eFxC-Xc7nDyGTXAQLWCb-nUHI1ygE2-6DJfHeo4eb74_XP-o7n7ezq-_3VV2JsVYSU-9Eg2R3lpPpWutr1VJ6ZQAJYignnknrDPOQ1vzmrZ1zVrBhOBcGS75Ofp68F0_tz04C3EcTKfXQ-jNsNPJBP22E8NSL9JGz4hSlPBi8PlgsDXRm7jQq_Q8xBJZl0MzQkoYQkSRkYPMDinnAfzfFZToPZe9XBcuunDRey5l5OP_0f4NHEEUwaej5zLFxa9QlrfGPvnQgWac8qYRNX8FKxWY9A</recordid><startdate>20061014</startdate><enddate>20061014</enddate><creator>van Bodegraven, A A</creator><creator>Mulder, Chris J J</creator><general>Section of Inflammatory Bowel Diseases,VU University medical centre, Amsterdam, The Netherlands%Department of Gastroenterology, VU University medical centre, Amsterdam, The Netherlands</general><general>Baishideng Publishing Group Co., Limited</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20061014</creationdate><title>Indications for 5-aminosalicylate in inflammatory bowel disease： IS the body of evidence complete</title><author>van Bodegraven, A A ; Mulder, Chris J J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-7f1f85907fccf17dbcf68638d85e85051f2fd5cdadfeb6361b662b5255338a373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenocarcinoma - prevention & control</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Colonic Neoplasms - prevention & control</topic><topic>Humans</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Mesalamine - pharmacokinetics</topic><topic>Mesalamine - therapeutic use</topic><topic>Review</topic><topic>Sulfasalazine - therapeutic use</topic><topic>Treatment Failure</topic><topic>Treatment Refusal</topic><topic>病理机制</topic><topic>结肠疾病</topic><topic>肠道炎症</topic><toplevel>online_resources</toplevel><creatorcontrib>van Bodegraven, A A</creatorcontrib><creatorcontrib>Mulder, Chris J J</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Bodegraven, A A</au><au>Mulder, Chris J J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Indications for 5-aminosalicylate in inflammatory bowel disease： IS the body of evidence complete</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2006-10-14</date><risdate>2006</risdate><volume>12</volume><issue>38</issue><spage>6115</spage><epage>6123</epage><pages>6115-6123</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>Mesalazine is a safe drug, although adverse events may be seen in a minority of patients. This applies also to pregnant women and children. The role of mesalazine in combination therapy to improve efficacy and concomitant drug pharmacokinetics, or in chemoprevention against-inflammatory bowel disease （IBD）-related colonic carcinoma has not yet been completely elucidated. Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance. Therefore, due to its superior safety profile and pharmacokinetic characteristics, mesalazine is preferable to sulphasalazine. This paper reviews the literature concerning mechanisms of action, indications and off-label use, pharmacokinetic properties and formulations, therapeutic efficacy, compliance, paediatric indications, chemoprevention, and safety issues and adverse event profile of mesalazine treatment versus sulphasalazine. It also highlights these controversies in order to clarify the potential benefits of mesalazines in IBD therapy and evidence for its use.</abstract><cop>United States</cop><pub>Section of Inflammatory Bowel Diseases,VU University medical centre, Amsterdam, The Netherlands%Department of Gastroenterology, VU University medical centre, Amsterdam, The Netherlands</pub><pmid>17036381</pmid><doi>10.3748/wjg.v12.i38.6115</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2006-10, Vol.12 (38), p.6115-6123 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4088103 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - prevention & control Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Colonic Neoplasms - prevention & control Humans Inflammatory Bowel Diseases - drug therapy Mesalamine - pharmacokinetics Mesalamine - therapeutic use Review Sulfasalazine - therapeutic use Treatment Failure Treatment Refusal 病理机制 结肠疾病 肠道炎症 |
| title | Indications for 5-aminosalicylate in inflammatory bowel disease： IS the body of evidence complete |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T17%3A22%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Indications%20for%205-aminosalicylate%20in%20inflammatory%20bowel%20disease%EF%BC%9A%20IS%20the%20body%20of%20evidence%20complete&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=van%20Bodegraven,%20A%20A&rft.date=2006-10-14&rft.volume=12&rft.issue=38&rft.spage=6115&rft.epage=6123&rft.pages=6115-6123&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v12.i38.6115&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200638005%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17036381&rft_cqvip_id=23139956&rft_wanfj_id=wjg200638005&rfr_iscdi=true |